SFMG Wealth Advisors’s Celgene Corp CELG Stock Holding History

SFMG Wealth Advisors’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-7,641	Closed	-$682K	–	174
2018 Q1	$682K	Sell	7,641 -210	-3%	-$20.2K	0.12%	55
2017 Q4	$819K	Buy	+7,851	New	+$886K	0.14%	52
2015 Q2	–	Sell	-2,198	Closed	-$253K	–	188
2015 Q1	$253K	Buy	+2,198	New	+$263K	0.02%	151

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFMG Wealth Advisors's CELG Position: Q2 2018 in Review

SFMG Wealth Advisors sold out of Celgene Corp (CELG) in Q2 2018, closing a stake of 7,641 shares — an estimated $682K sold.

SFMG Wealth Advisors first reported a position in CELG in Q1 2015 and held it in 3 quarters. The position peaked at $819K in Q4 2017. 1,360 funds tracked by Wall St. Rank hold CELG as of Q2 2018.

SFMG Wealth Advisors reported no remaining Celgene Corp position as of Q2 2018 after selling out during the quarter.
SFMG Wealth Advisors sold 7,641 Celgene Corp shares in Q2 2018, an estimated $682K.
SFMG Wealth Advisors first reported a position in Celgene Corp in Q1 2015 and held it in 3 quarters.
SFMG Wealth Advisors's Celgene Corp position peaked at $819K in Q4 2017.
1,360 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2018.

Based on SFMG Wealth Advisors's 13F filing for Q2 2018, filed 8 Aug 2018.